C. Tural

B. Clotet, G. Sirera, C. Tural, 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: is it really different, and if so, why?

C. Tural, F. Degos, 2007, Journal of hepatology.

Randomized trial comparing pegylated interferon α‐2b versus pegylated interferon α‐2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients

C. Tural, J. Gatell, J. Mallolas, 2009, Hepatology.

IFN-γ response on T-cell based assays in HIV-infected patients for detection of tuberculosis infection

C. Tural, A. Lacoma, I. Latorre, 2010, BMC infectious diseases.

Systemic lupus erythematosus and pernicious anemia in an 82-year-old woman.

C. Tural, J. Juncà, A. Cuxart, 1991, The Journal of rheumatology.

HLA-B*57 and IFNL4-Related Polymorphisms Are Associated With Protection Against HIV-1 Disease Progression in Controllers

B. Walker, C. Tural, Xu G. Yu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of the interleukin‐6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients

Michael J. Rausch, R. Bruno, B. Clotet, 2007, Hepatology.

Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients.

B. Clotet, C. Tural, D. Fuster, 2005, The Journal of antimicrobial chemotherapy.

IFNL4 ss469415590 variant is a better predictor than rs12979860 of pegylated interferon-alpha/ribavirin therapy failure in hepatitis C virus/HIV-1 coinfected patients

B. Clotet, C. Tural, S. Franco, 2014, AIDS.

Deciphering the Interleukin 28B Variants That Better Predict Response to Pegylated Interferon-α and Ribavirin Therapy in HCV/HIV-1 Coinfected Patients

B. Clotet, C. Tural, S. Franco, 2012, PloS one.

Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected Patients

B. Clotet, C. Tural, S. Franco, 2011, Journal of Virology.

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

R. Bruno, B. Clotet, C. Tural, 2011, The Journal of infectious diseases.

Genetic Variation in IL 28 B and Treatment-induced Clearance of Hepatitis C Virus in HIV-Positive Patients With Acute and Chronic Hepatitis C

Michael J. Rausch, R. Bruno, B. Clotet, 2011 .

The continuum of HIV care in Catalonia

C. Tural, J. Miro, Gemma Navarro, 2015, AIDS care.

Estimated liver fibrosis and its impact on all-cause mortality of HCV-monoinfected and HCV/HIV-coinfected drug users.

C. Tural, C. Rey-Joly, J. Tor, 2011, Current HIV research.

Oral solid form of primary effusion lymphoma mimicking plasmablastic lymphoma.

J. Mate, S. Serrano, C. Tural, 2004, Human pathology.

Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.

C. Tural, J. Mallolas, C. Quereda, 2013, Journal of hepatology.

Hyaluronic acid, transforming growth factor‐β1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co‐infection

C. Tural, I. Ojanguren, C. Rey-Joly, 2009, Journal of viral hepatitis.

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations

C. Tural, J. Miro, V. Soriano, 2004, Journal of viral hepatitis.

Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients

C. Tural, M. Díaz-Menéndez, J. Macías, 2014, AIDS.

Comparison of Glycemic Variability and Hypoglycemic Events in Hospitalized Older Adults Treated with Basal Insulin plus Vildagliptin and Basal–Bolus Insulin Regimen: A Prospective Randomized Study

C. Tural, G. Umpierrez, M. Puig-Domingo, 2022, Journal of clinical medicine.

Eosinophilic fasciitis and non‐Hodgkin lymphoma

C. Tural, I. Ojanguren, J. Juncà, 1994, European journal of haematology.

Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration

J. Sterne, O. Kirk, C. Tural, 2015, Journal of acquired immune deficiency syndromes.

Hepatotoxicity of antiretroviral drugs in HIV HCV patients with congenital coagulopathies followed at an Haemophilia Unit during a decade

C. Tural, S. Sauleda, J. Esteban, 2006 .

Single nucleotide polymorphisms in PNPLA3, ADAR-1 and IFIH1 are associated with advanced liver fibrosis in patients co-infected with HIV-1//hepatitis C virus

B. Clotet, C. Tural, S. Franco, 2021, AIDS.

Hydroxychloroquine pre-exposure prophylaxis for COVID-19 in healthcare workers

C. Tebé, B. Clotet, C. Tural, 2020, The Journal of antimicrobial chemotherapy.

Concomitant nevirapine therapy is associated with higher efficacy of pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients.

C. Tural, M. Laguno, M. Crespo, 2010 .

Baseline Factors associated with Haematological Toxicity that Leads to a Dosage Reduction of Pegylated Interferon-α2a and Ribavirin in HIV- and HCV-Coinfected Patients on HCV Antiviral Therapy

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral Therapy.

Changes in T-cell subsets in HIV–HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment

B. Clotet, C. Tural, B. Autran, 2010, Antiviral therapy.

Quantitative HIV-1 RNA as a marker of clinical stability and survival in a cohort of 302 patients with a mean CD4 cell count of 300 x 10(6)/l.

B. Clotet, J. Martinez-Picado, L. Ruiz, 1996, AIDS.

Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3.

B. Clotet, G. Sirera, C. Tural, 2007, The Journal of antimicrobial chemotherapy.

Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.

B. Clotet, L. Ruiz, J. Romeu, 1998, The Journal of infectious diseases.

Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection

C. Tural, D. Cooper, D. Dieterich, 2007, AIDS.

Differences in Virological Response to Pegylated Interferon and Ribavirin between Hepatitis C Virus (Hcv)-Monoinfected and HCV–Hiv-Coinfected Patients

B. Clotet, G. Sirera, C. Tural, 2008, Antiviral therapy.

Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus‐coinfected patients

C. Tural, J. Macías, Á. Burgos, 2010, Journal of viral hepatitis.

European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV‐infected adults

R. Bruno, C. Tural, V. Soriano, 2008, HIV medicine.

Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.

A. Mocroft, O. Kirk, C. Tural, 2005, The Journal of infectious diseases.

Temporal arteritis and polymyalgia rheumatica masquerading as panarteritis nodosa.

C. Tural, D. López, A. Olivé, 1993, Clinical and experimental rheumatology.

Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy

C. Tural, R. Schuurman, J. Casado, 1999 .

Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy. Spanish CMV-AIDS Study Group.

C. Tural, R. Schuurman, J. Casado, 1999, AIDS.

Therapeutic challenge for Isospora belli enteritis in an AIDS patient who developed Lyell syndrome after co-trimoxazole therapy.

J. Carles, B. Clotet, C. Tural, 1989, The American journal of gastroenterology.

Anti-Intrinsic Factor Antibodies in Systemic Lupus Erythematosus

C. Tural, J. Juncà, A. Olivé, 1993, Lupus.

HBV Primary Drug Resistance in Newly Diagnosed HIV–Hbv-Coinfected Individuals in Spain

C. Tural, E. Poveda, V. Soriano, 2011, Antiviral therapy.

Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.

C. Tural, V. Soriano, J. Macías, 2008, The Journal of antimicrobial chemotherapy.

Quality of Life, Emotional Status, and Adherence of HIV‐1‐Infected Patients Treated With Efavirenz Versus Protease Inhibitor‐Containing Regimens

R. Paredes, B. Clotet, J. Romeu, 2002, Journal of acquired immune deficiency syndromes.

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients

G. Sirera, C. Tural, I. Ojanguren, 2003, Journal of viral hepatitis.

Pegylated interferon a 2 a plus ribavirin versus pegylated interferon a 2 b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Clinical Society ( EACS ) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults

R. Bruno, C. Tural, V. Soriano, 2008 .

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

HIV/hepatitis C virus-coinfected patients who achieved sustained virological response are still at risk of developing hepatocellular carcinoma

C. Tural, J. Pineda, A. Rivero, 2014, AIDS.

Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.

C. Tural, J. Mallolas, C. Quereda, 2009, The Journal of antimicrobial chemotherapy.

Pegylated interferon a 2a plus ribavirin versus pegylated interferon a 2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients

C. Tural, J. Mallolas, C. Quereda, 2009 .

Detection of hepatitis C virus antibodies in oral fluid specimens for prevalence studies

C. Tural, J. Grifols, A. Esteve, 2008, European Journal of Clinical Microbiology and Infectious Diseases.

Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

C. Tural, J. Mallolas, C. Quereda, 2009, Hepatology.

Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.

B. Clotet, C. Tural, S. Franco, 2007, Virus research.

Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.

R. Paredes, B. Clotet, L. Ruiz, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy

C. Tural, G. Carcelain, R. Tubiana, 2001, AIDS.

Effect of An Induction Period of Pegylated Interferon-α2A and Ribavirin on Early Virological Response in HIV–HCV-Coinfected Patients: Results from the Coral-2 Study

R. Paredes, B. Clotet, C. Tural, 2011, Antiviral therapy.

Ability of treatment week 12 viral response to predict long-term outcome in genotype 1 hepatitis C virus/HIV coinfected patients

D. Podzamczer, C. Tural, M. Crespo, 2010, AIDS.

Management of HIV/hepatitis C virus-coinfected patient non-responders to hepatitis C virus antiviral therapy and relapsers

B. Clotet, C. Tural, R. Planas, 2007, Current opinion in HIV and AIDS.

Mitochondrial Effects of a 24-Week Course of Pegylated-Interferon plus Ribavirin in Asymptomatic HCV/HIV Co-Infected Patients on Long-Term Treatment with Didanosine, Stavudine or Both

Ò. Miró, B. Clotet, C. Tural, 2004, Antiviral therapy.

High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.

R. Paredes, B. Clotet, L. Ruiz, 1999, Journal of acquired immune deficiency syndromes.

Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.

R. Paredes, B. Clotet, J. Martinez-Picado, 2003, The Journal of infectious diseases.

Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART

G. Feldmann, B. Clotet, C. Tural, 2008, AIDS.

Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era.

B. Clotet, G. Sirera, C. Tural, 2007, AIDS research and human retroviruses.

Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy.

C. Tural, A. Oriol, J. Ribera, 2003, Journal of acquired immune deficiency syndromes.

Neoplasms and infections as the main causes of death in patients in complete response to HIV‐related non‐Hodgkin lymphoma in the combination antiretroviral therapy era: a study out of a series of 146 patients

C. Tural, J. Ribera, E. Feliú, 2013, British journal of haematology.

Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes.

B. Clotet, L. Ruiz, J. Romeu, 1999, Scandinavian journal of infectious diseases.

Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.

B. Clotet, G. Sirera, C. Tural, 2000 .

GB virus C coinfection in advanced HIV type-1 disease is associated with low CCR5 and CXCR4 surface expression on CD4+ T-cells

B. Clotet, C. Tural, J. Rockstroh, 2010, Antiviral therapy.

HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers.

B. Walker, C. Tural, M. Lichterfeld, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.

C. Tural, T. Pumarola, J. Miro, 2011, Enfermedades infecciosas y microbiologia clinica.

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

Lidia Ruiz, Bonaventura Clotet, B. Clotet, 2002, AIDS.

The effect of injecting drug use history on disease progression and death among HIV‐positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis

O. Kirk, A. d’Arminio Monforte, R. Weber, 2012, HIV medicine.

Effect of liver fibrosis on long-term mortality in HIV/hepatitis C virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era.

B. Clotet, C. Tural, I. Ojanguren, 2012, AIDS research and human retroviruses.

Liver stiffness measurement versus liver biopsy to predict survival and decompensations of cirrhosis among HIV/hepatitis C virus-coinfected patients

C. Tural, J. Macías, J. Pineda, 2013, AIDS.

Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy

C. Tural, V. Soriano, Jesús Santos, 2013, AIDS.

Recently acquired HIV infection in Spain (2003–2005): introduction of the serological testing algorithm for recent HIV seroconversion

C. Tural, T. Pumarola, J. Miro, 2008, Sexually Transmitted Infections.

Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy.

B. Clotet, J. Martinez-Picado, L. Montaner, 2016, The Journal of infectious diseases.

Anti-neutrophil cytoplasmic auto-antibodies-associated vasculitis with pulmonary and renal involvement

C. Tural, G. Pintos-Morell, M. Naranjo, 1993, European Journal of Pediatrics.

[Wegener's granulomatosis: a report of 6 patients].

C. Tural, C. Rey-Joly, A. Cuxart, 1992, Medicina clínica (Ed. impresa).

Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08).

C. Tural, T. Pumarola, J. Miro, 2012, European journal of public health.

Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral therapy.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Estimating the HIV undiagnosed population in Catalonia, Spain: descriptive and comparative data analysis to identify differences in MSM stratified by migrant and Spanish-born population

C. Tural, J. Miro, J. Caylà, 2018, BMJ Open.

Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.

R. Paredes, L. Ruiz, J. Romeu, 1999, Antiviral therapy.

Asymptomatic HIV

B. Clotet, J. Romeu, C. Tural, 1988, Neurology.

[Recommendations for non-occupational postexposure HIV prophylaxis. Spanish Working Group on Non-Occupational Postexposure HIV Prophylaxis of the Catalonian Center for Epidemiological Studies on AIDS and the AIDS Study Group].

C. Tural, J. del Romero, J. Casabona, 2002, Enfermedades infecciosas y microbiologia clinica.

Immunogenicity and reactogenicity of a combined hepatitis A and B vaccine in young adults.

C. Tural, R. Dal-Ré, J. Bayas, 1996, Vaccine.

[Clinical-epidemiological characteristics and antiretroviral treatment trends in a cohort of HIV infected patients. The PISCIS Project].

D. Podzamczer, B. Clotet, C. Tural, 2005, Medicina clinica.

Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort.

D. Podzamczer, B. Clotet, C. Tural, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects.

B. Clotet, J. Martinez-Picado, L. Ruiz, 2004, AIDS research and human retroviruses.

Hepatitis B (HBV) and Hepatitis C (HCV) in the EuroSIDA Cohort: Prevalence and Impact on Mortality, Aids Progression and Response to HAART.

A. Mocroft, O. Kirk, F. Antunes, 2004 .

ADAR1 affects HCV infection by modulating innate immune response

B. Clotet, C. Tural, S. Franco, 2018, Antiviral research.

The Magnitude of Interferon-γ Responses to Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression

B. Clotet, J. Martinez-Picado, L. Ruiz, 2008, Journal of acquired immune deficiency syndromes.

The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients

C. Tural, J. Arribas, C. Quereda, 2011, AIDS.

Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC

B. Clotet, J. Martinez-Picado, L. Ruiz, 1996, AIDS.

Alleles at rs4273729 in the chromosome 6 do not predict response to peg-interferon-α and ribavirin therapy in hepatitis C virus/HIV-1-coinfected patients.

B. Clotet, C. Tural, S. Franco, 2012, AIDS.

Normalization of circulating plasma levels of miRNAs in HIV-1/HCV co-infected patients following direct-acting antiviral–induced sustained virologic response

C. Tural, S. Franco, J. Llibre, 2023, Heliyon.

Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections

C. Tural, S. Franco, Daniela Buccione, 2021, AIDS.

Comparison of the prognostic value of liver biopsy and FIB-4 index in patients coinfected with HIV and hepatitis C virus.

C. Tural, J. Mallolas, M. Crespo, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co‐infection

C. Tural, J. del Romero, J. Pineda, 2009, Journal of viral hepatitis.

Influence of the type of pegylated interferon on the onset of depressive and neuropsychiatric symptoms in HIV-HCV coinfected patients

R. Paredes, B. Clotet, C. Tural, 2007, AIDS care.

Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.

B. Clotet, G. Sirera, C. Tural, 2006, AIDS research and human retroviruses.

603 Insulin resistance in co-infected HCV/HIV patients: A negative factor influencing sustained response to peginterferon plus ribavirin

B. Clotet, C. Tural, R. Planas, 2006 .

Transient Elastography for Predicting Liver-Related Events in CirrhoticHIV-Infected Patients

C. Tural, J. Miro, C. Quereda, 2017 .

Progression of liver fibrosis in HIV/hepatitis C virus‐coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline

B. Clotet, C. Tural, I. Ojanguren, 2014, HIV medicine.

Optimal Use of Transient Elastography and Acoustic Radiation Force Impulse to Stage Liver Fibrosis in HIV/HCV‐Coinfected Patients in Clinical Practice

B. Clotet, C. Tural, N. Pérez-Álvarez, 2018, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.

B. Clotet, G. Sirera, C. Tural, 2004, AIDS research and human retroviruses.

[Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients].

B. Clotet, E. Negredo, G. Sirera, 2005, Medicina clinica.

Results of a Study of Prolonging Treatment with Pegylated Interferon-α2A plus Ribavirin in HIV/HCV-Coinfected Patients with No Early Virological Response

B. Clotet, G. Sirera, C. Tural, 2005, Antiviral therapy.

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.

D. Podzamczer, C. Tural, J. Miro, 2015, The Journal of antimicrobial chemotherapy.

Sensitivity of seven HIV subtyping tools differs among subtypes/recombinants in the Spanish cohort of naïve HIV-infected patients (CoRIS).

C. Tural, Á. Holguín, Gemma Navarro, 2011, Antiviral research.

[HIV infection in immigrants in Spain: Epidemiological characteristics and clinical presentation in the CoRIS Cohort (2004-2006)].

C. Tural, J. Miro, M. Salavert, 2009, Enfermedades Infecciosas y Microbiologia Clinica.

Changing utilization of Stavudine (d4T) in HIV‐positive people in 2006–2013 in the EuroSIDA study

J. Nielsen, C. Leen, P. Vanhems, 2015, HIV medicine.

Prevalence and genotypes of GB virus C/hepatitis G virus (GBV‐C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: Evidence of GBV‐C/HGV sexual transmission

B. Clotet, G. Sirera, C. Tural, 1998, Journal of medical virology.

Prospective Randomized Two‐Arm Controlled Study To Determine the Efficacy of a Specific Intervention To Improve Long‐Term Adherence to Highly Active Antiretroviral Therapy

B Clotet, B. Clotet, L. Ruiz, 2000, Journal of acquired immune deficiency syndromes.

Sustained virological response to interferon plus ribavirin reduces liver‐related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus

C. Tural, J. Mallolas, C. Quereda, 2009, Hepatology.

[Evaluation of the costs of transient elastography (FibroScan(®)) in the diagnosis of liver fibrosis in HIV patients with hepatitis C virus].

C. Tural, I. Oyagüez, M. Casado, 2012, Enfermedades infecciosas y microbiologia clinica.

Association between visceral abdominal fat accumulation and severity of liver fibrosis in nondiabetic individuals coinfected by HIV and HCV.

B. Clotet, C. Tural, S. Franco, 2020, AIDS research and human retroviruses.

R. Paredes, B. Clotet, J. Romeu, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Prevalence and factors associated with liver steatosis as measured by transient elastography with controlled attenuation parameter in HIV-infected patients

C. Tural, M. Díaz-Menéndez, J. Macías, 2014, AIDS.